NDAINTRAVENOUSINJECTABLE
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AMMONIA N 13 (nh3n13) by Medica Corp is radiopharmaceutical activity [moa]. First approved in 2007.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ammonia N 13 is a radioactive diagnostic agent administered intravenously for positron emission tomography (PET) imaging. It is used to assess regional myocardial perfusion and cerebral blood flow in clinical settings. The drug works through radiopharmaceutical activity, leveraging the N-13 isotope's decay characteristics for diagnostic imaging.
LOE Approaching
Limited commercial scale with minimal linked job opportunities suggests a niche diagnostic product with small brand team footprint.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This is a niche diagnostic radiopharmaceutical with minimal career movement or hiring activity. Professionals working on Ammonia N 13 typically occupy specialized roles in nuclear medicine or diagnostic imaging with limited advancement pathways.
Radiopharmaceutical SpecialistDiagnostic Product Manager
Worked on AMMONIA N 13 at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.